Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944500 · ClinicalTrials.gov registry record · Phase 4
Saxenda: Underlying Mechanisms and Clinical Outcomes
A Phase 4 study of Obesity, sponsored by Beth Israel Deaconess Medical Center.
- Active
- Registry status
- Phase 4
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT02944500 is a Phase 4 study of Obesity that is active but no longer recruiting, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 28 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02944500, a Phase 4 study of Obesity, is active but no longer recruiting, sponsored by Beth Israel Deaconess Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG liraglutide
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center General Clinical Research Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-11 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02944500
The ClinicalTrials.gov registry entry for NCT02944500 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02944500 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02944500 about?
NCT02944500 is a clinical study titled "Saxenda: Underlying Mechanisms and Clinical Outcomes". The purpose of this protocol is to investigate the effect of treatment with the study drug Liraglutide, a GLP-1 receptor agonist, on centers of the brain that control appetite and food intake.
What is the current status of trial NCT02944500?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 28 participants. The study started on 2016-11. Estimated completion is 2026-06.
What conditions does trial NCT02944500 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT02944500?
The interventions under investigation include: Placebo (OTHER), liraglutide (DRUG).
Who is sponsoring clinical trial NCT02944500?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02944500 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.